Viridian Therapeutics, Inc. (0K1R.L) LSE

18.65

+0.1476(+0.80%)

Updated at September 08 02:34PM

Currency In USD

Valuation

Market Cap1.3B
Enterprise Value1.22B
P/E Ratio-4.44
PEG Ratio-8.55
Price/Sales Ratio5,012.2
Price/Book Ratio2.96
Enterprise/Revenue4,697.5
Enterprise/EBITDA-4.21

Fiscal Year

Fiscal YearDecember 31, 2024
Most Recent QuarterJune 30, 2025

Profitability

Profit Margin-1,128.07
Operating Margin-1,218.31

Management Effectiveness

Return On Assets-0.59
Return On Equity-0.55

Income Statement

Revenue302,000
Revenue/Share0
Gross Profit302,000
EBITDA-265.66M
Net Income-269.95M
Diluted EPS-3.98

Balance Sheet

Total Cash563.36M
Total Cash/Share6.9
Total Debt21.34M
Total Debt/Equity0.04
Current Ratio11.01
Book Value Per Share6.31

Price History

52-Week Change25.61
52-Week High29.3
52-Week Low10.98
Moving Average 50 Days20.02
Moving Average 200 Days19.53

Statistics

Average Volume682
Shares Outstanding81.66M
% Held by InstitutionsN/A

Dividend And Splits

Trailing Annual Dividend Rate0
Trailing Annual Dividend Yield0
Payout Ratio0
Last Split Factor1:15
Last Split DateSeptember 21, 2021